Anavex Life Sciences Corp (AVXL)

[nidan7500]

boi

If these progress as planned (and with a few minor approvals en route), he then can seek a broad CNS platform basket approval without having to undertake multiple, full blown Phase 3 trials in each indication.

Yup, I do think that is one possibility. No doubt this would require success w/first attempts after careful FDA scrutiny. Perhaps the best approach available for rare CNS diseases.